MedTrace Logo

Travoprost Five Day Posology Study

NCT01114893 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-06-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.

Conditions

Interventions

DRUG

Travoprost 0.004%

1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days

DRUG

Travoprost Vehicle

1 drop in each eye 8 times daily for 5 days

DRUG

Travoprost (Groups A, B and C)

1 drop in each eye 8 times daily for 5 days

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114893 on ClinicalTrials.gov